当前位置: 首页 > 详情页

Elevated serum ferritin level as a predictor of reduced survival in patients with sporadic amyotrophic lateral sclerosis in China: a retrospective study

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]College of Medicine, Nankai University, Tianjin, China [2]Department of Neurology, Chinese PLA General Hospital, Beijing, China [3]Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
出处:
ISSN:

关键词: Amyotrophic lateral sclerosis iron metabolism ferritin prognosis survival

摘要:
Objective: The objective of this study was to compare iron metabolic variables in the serum and cerebrospinal fluid (CSF) of patients with sporadic amyotrophic lateral sclerosis (sALS) with those of patients with multiple system atrophy (MSA) and control subjects. We also assessed the correlations of these variables with sALS progression and severity and estimated their roles in predicting prognosis. Methods: We retrospectively collected iron metabolic parameters, including serum levels of iron, ferritin, transferrin levels and total iron binding capacity and the CSF level of ferritin, from 435 sALS patients, 176 MSA patients and 431 control subjects. Results: Serum ferritin levels were significantly higher in the sALS group compared with the MSA and control groups in both males (p=0.001 and p<0.0001, respectively) and females (p=0.034 and p<0.0001, respectively). However, serum transferrin levels were significantly lower in females of the sALS group compared with the MSA (p=0.016) and control (p=0.015) groups. The CSF ferritin level and the serum levels of total iron binding capacity and iron were similar among the sALS, MSA and control groups. Survival analysis demonstrated that higher serum ferritin levels were predictors of reduced survival of sALS patients. No correlations between iron metabolic variables and clinical parameters were found. Conclusion: An elevated serum ferritin level is associated with reduced survival of sALS patients. However, the levels of iron metabolic parameters were not associated with clinical deterioration or disease severity at diagnosis.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 3 区 临床神经病学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 临床神经病学
JCR分区:
出版当年[2017]版:
Q2 CLINICAL NEUROLOGY
最新[2023]版:
Q2 CLINICAL NEUROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]College of Medicine, Nankai University, Tianjin, China
通讯作者:
通讯机构: [1]College of Medicine, Nankai University, Tianjin, China [2]Department of Neurology, Chinese PLA General Hospital, Beijing, China [*1]Chinese PLA General Hospital, Beijing, China,College of Medicine, Nankai University, Tianjin, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院